About Von Willebrand Disease — What is VWD
Humat-P for VWD — High-Quality VWF
Using Humate-P
Dosage Calculator
Mix2Vial/Smaller Diluent
Reimbursement and Prescribing Information
The CSL Behring Commitment
Resources & Tools
News & Events
Important Safety Information
Prescribing Information
Dosing Calculator
VWF Densitometric Analysis
Request More Information
For Patients

Mix2Vial™ and Smaller Diluent

Recent Product Updates

New, enhanced prescribing information (PI) is available for Humate-P®, and includes:

  • Clinical data on use of Humate-P® in surgical patients
  • Expanded information on dosing
  • New virus reduction capacity

View the new prescribing information now.

Now Available:

  • Smaller diluent
  • Mix2Vial™ Needle-Free Transfer Device

50% less diluent in all assay sizes.

This means:

  • Less infusion time
  • Smaller vials and packaging
  • Less storage space

Mix2Vial™ is a simple way to reconstitute Humate-P® offering:

  • Needle-free transfer device
  • Less risk of accidental injury
  • Less time spent preparing product
  • Simple process encourages independence
  • Built-in filter
  • For use with all Luer-Lok® syringes

For more information on Mix2Vial™, call CSL Behring Customer Support at 1800-683-1288

View a virtual step-by-step demonstration of how Mix2Vial works, please click here.

Your patients can self-infuse Humate-P at home using the Mix2Vial. View the Home Infusion Video.

Reminder: When stored at refrigerator temperature, 2°–8°C (36°–46°F), Humate-P® is stable for the period indicated by the expiration date on its label. Within this period, Humate-P® may be stored at room temperature not to exceed 30°C (86°F), for up to six months.

Smaller Diluent





mix2vial
View Mix2Vial™ Demonstration

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P®.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.